DOSIsoft unit gives PLANET a theranostics focus
DOSIsoft Theranostics will operate within the DOSIsoft group, with its own partnerships and investment strategy centered on PLANET software.
DOSIsoft has created DOSIsoft Theranostics as a dedicated business focused on software for personalized nuclear medicine and theranostics workflows. The company announced the new entity ahead of the SNMMI 2026 annual meeting in Los Angeles.
The unit will operate within the DOSIsoft group while pursuing its own partnerships, innovation agenda, and investment strategy, according to the announcement. DOSIsoft said the structure is intended to support broader routine clinical use of theranostics software.
PLANET is the product anchor for the new entity. The platform includes voxel-based multiradionuclide dosimetry capabilities and multimodality DICOM interoperability, according to DOSIsoft.
FDA documentation for PLANET Onco Dose 3.2 describes the software as a standalone system for managing, processing, displaying, and analyzing anatomical and functional images. The cleared indications include tools for diagnosis aid, contouring, therapy response assessment, and internal dosimetry computation for radionuclide-based therapies.
The FDA filing also states that PLANET Onco Dose is intended for retrospective dose determination and should not be used to deviate from approved radioactive product dosing and administration instructions. Supported modalities include CT, MRI, SPECT, PET, XA, planar scintigraphy, RT Struct, and RT Dose in DICOM format.
DOSIsoft said the theranostics entity will be present at SNMMI 2026 at booth #1358. The company said its broader installed base includes more than 1,000 installations across 800+ hospital centers in 80 countries.
Company:DOSIsoft
Sources
- 510(k) Summary K241765, PLANET Onco Dose 3.2. Regulatory filing
About the author
RadiologySignal.com writersEditorial Team
Radiology Signal Staff covers developments across medical imaging, radiology AI, imaging informatics, clinical research, and radiology business. The team monitors primary sources, peer-reviewed studies, company announcements, society updates, and healthcare industry news to deliver concise reporting for imaging professionals.
More from this section
Pathology support broadens MedDream viewer scope
Version 8.9.0 is scheduled for June 2026 through aycan and will add support for pathology workflows and saving reconstructed MPR viewports as new study series.
Vault-ready proton system headed to Tam Anh
Mevion said the S250-FIT installation would be Vietnam’s first proton therapy system, with operation expected as early as late 2027 at Tam Anh’s Phu My Hung facility.
I-MED sale gives Jardines 215-clinic radiology network
Jardine Matheson will acquire 100% of I-MED Radiology Network in a deal valued at A$3.4B, including I-MED’s minority stake in Harrison.ai.
Expected Russell addition puts Hyperfine in small-cap benchmarks
FTSE Russell’s preliminary June reconstitution list includes Hyperfine, with index changes set to take effect after U.S. markets close on June 26.
Curium approach puts Lantheus deal value near $7B
Lantheus is weighing a potential sale after an approach from Curium Pharma, while company filings show recent Pylarify pressure and pending PET regulatory milestones.
Niowave Lansing site to scale Ac-225 supply by 2028
The Lansing, MI, site will house superconducting linear accelerators and radiochemistry systems to support scalable actinium-225 production, with completion expected in 2028.
30-year GE-UW tie expands into CT and theranostics research
The collaboration will focus on CT and molecular imaging technologies for cardiology, oncology, and theranostics workflows at UW Medicine Radiology facilities in Seattle.
Recall issues and isotope shortages weigh on Radnostix Q1 revenue
The radioisotope-focused company reported $2.38M in Q1 revenue, citing recall impacts, isotope shortages, and Cobalt-60 hot cell downtime.
Ephemeral to build AI data platform for Plus CNS oncology programs
The companies will develop an AI platform to integrate therapeutic, diagnostic, and bioinformatics data across Plus Therapeutics’ CNS oncology programs.
Fujifilm balloon-free EBUS scope targets pulmonary setup time
The EB-710US Ultrasound Bronchoscope is designed for pulmonary procedures and will be demonstrated at the American Thoracic Society Conference.
ACIST Pro brings contrast tracking upgrade to U.S. cath labs
The Bracco company received U.S. clearance and launched ACIST Pro, a variable-rate contrast management system for image-guided cardiovascular procedures.
Braid Health launches $199 radiology second-opinion service
Patients can upload MRI, CT, X-ray, or ultrasound files and receive a written second opinion from a board-certified U.S. radiologist.